

Digoxin In NASH (CODIN)

NCT06588699

Status	RECRUITING
Phase	Phase 2
Sponsor	Yale University
Enrollment	144 participants

Key Eligibility Criteria

Inclusion (3)

- Stable body weight (d 5% self-reported change in body weight) in the 30 days prior to screening
- Biopsy-confirmed non-alcoholic steatohepatitis (NASH) as defined by the NASH clinical research network (NASH CRN) histological scoring system, with non-alcoholic fatty liver disease score (NAS) e4 and with a score e1 for each of the three components (steatosis, hepatocellular ballooning, and lobular inflammation) on a liver biopsy performed within 6 months of screening
- Histological fibrosis stage 2 or 3 based on pathologist evaluation of a liver biopsy performed up to 6 months before screening

Exclusion (34)

- Liver-related:
- Documented causes of chronic liver disease other than NASH
- History or clinical evidence of cirrhosis or portal hypertension
- History of positive HBsAg, positive anti-HIV, positive HCV-RNA
- AST or ALT \geq 5 times upper limit of normal (ULN) at screening
- ... and 29 more (see full listing online)

Locations (2 total)

Yale New Haven Health, New Haven, Connecticut, United States
Yale New Haven Hospital, New Haven, Connecticut, United States